Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 6c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.69), $0.06 worse than the analyst estimate of ($0.63).

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight